Immunotherapy for HER-2 positive breast cancer

Immunotherapy is a developing treatment for advanced breast cancer. Immunotherapy has clinical significance for the treatment of triple-negative breast cancers and human epidermal growth factor receptor-2 positive (HER2+) breast cancers. As a proved effective passive immunotherapy, clinical applicat...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-03, Vol.13, p.1097983-1097983
Main Authors: Yang, Tingting, Kang, Lihua, Li, Dan, Song, Yanqiu
Format: Article
Language:English
Subjects:
active immunotherapy
adoptive T-cell immunotherapies
breast cancer
HER2
immune checkpoint inhibitors
Oncology
passive immunotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy is a developing treatment for advanced breast cancer. Immunotherapy has clinical significance for the treatment of triple-negative breast cancers and human epidermal growth factor receptor-2 positive (HER2+) breast cancers. As a proved effective passive immunotherapy, clinical application of the monoclonal antibodies trastuzumab, pertuzumab and T-DM1 (ado-trastuzumab emtansine) has significantly improved the survival of patients with HER2+ breast cancers. Immune checkpoint inhibitors that block programmed death receptor-1 and its ligand (PD-1/PD-L1) have also shown benefits for breast cancer in various clinical trials. Adoptive T-cell immunotherapies and tumor vaccines are emerging as novel approaches to treating breast cancer, but require further study. This article reviews recent advances in immunotherapy for HER2+ breast cancers.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1097983